Compare Incyte Corporation (INCY) vs Rent the Runway Inc (RENT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Rent the Runway Inc — how do they compare? Incyte Corporation trades at $112.79 (market cap $22.85B), while Rent the Runway Inc trades at $1.77 (market cap $61.75M). The key difference: Incyte Corporation is far larger — about 370× Rent the Runway Inc's market cap, and Incyte Corporation is trading nearer its 52-week high, Rent the Runway Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Rent the Runway Inc for 56 Days on average.
| INCY | RENT | |
|---|---|---|
Market Cap | $22.85B | $61.75M |
Volume | 1,927,029 | 193,323 |
Sector | Health | Consumer Cyclical |
52-Week High | $129.93 | $9.39 |
52-Week Low | $83.80 | $1.55 |
Typical Hold Time | 33 Days | 56 Days |
Enterprise Value | $18.35B | $228.75M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.75, down 0.61% on the day, with a bearish technical signal despite strong fundamentals. The company reported robust 2025 results with $5.14B revenue and $1.29B net income, showing significant margin expansion. Recent FDA approval for Atebrioz and pipeline progress support growth prospects beyond JAKAFI's 2029 exclusivity loss. Analyst consensus is bullish with a $132.43 price target, though technical indicators show selling pressure near key resistance.
Outlook remains positive driven by pipeline diversification and operational leverage, but near-term technical weakness and reliance on JAKAFI transition pose risks. The stock offers value with a 14.36 P/E ratio and strong profitability metrics, though investors should monitor execution on the $4B non-JAKAFI sales target and quarterly earnings consistency.
Rent the Runway (RENT) trades at $1.83, up 8.93% today, with a bullish technical signal despite mixed moving averages and oscillators. The company reported Q2 2026 revenue growth of 20.8% year-over-year to $97.7 million, with improving gross margins, and appointed Paige Thomas as CEO. However, the stock faces negative shareholder equity of -$182.5 million and a high debt-to-asset ratio of 139.62% as of 2025, though 2026 projections show a return to net profitability.
The outlook is cautiously optimistic, with analyst consensus at 42.1% buy ratings and no sell ratings, but legal investigations and high leverage pose significant risks. Revenue growth and margin expansion are key catalysts, yet investor confidence is tempered by ongoing financial instability and negative equity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Rent the Runway Inc
Rent the Runway Inc is an e-commerce platform that allows users to rent, subscribe, or buy designer apparel and accessories.
Read more on RENT →
